https://scholars.lib.ntu.edu.tw/handle/123456789/542194
標題: | Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis | 作者: | Chou C.-T. Tsai C.-Y. Liang T.-H. Chang T.-M. Lai C.-H. Wei C.-C. Chen K.-H. Lin S.-C. CHIA-LI YU Liou L.-B. Luo S.-F. Lee C.-S. Hsue Y.-T. Huang C.-M. Chen J.-H. Lai N.-S. Cheng H.-H. Cheng T.-T. Lai H.-M. Tsai W.-C. Yen J.-H. Lu L.-Y. Chang C.-P. |
關鍵字: | Ankylosing spondylitis; Chinese; Efficacy; Etanercept; Partial remission | 公開日期: | 2010 | 卷: | 20 | 期: | 6 | 起(迄)頁: | 580-587 | 來源出版物: | Modern Rheumatology | 摘要: | Tumor necrosis factor-alpha (TNF-α) inhibitors including etanercept have been demonstrated to be very effective in severe ankylosing spondylitis (AS) in Caucasian patients. However, clinical efficacy of etanercept to treat active AS in Chinese patients has not been reported. In this study, a prospective, open-label trial of etanercept (25 mg BIW), involving 46 AS patients from 16 medical centers of Taiwan, was conducted. Questionnaire was utilized to record demographic data and clinical parameters, including Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Global Index (BASGI), Assessment in Ankylosing Spondylitis (ASAS) 20, 50, and 70, and others, before and at different time intervals after etanercept treatment. Laboratory tests including blood chemistry, hematology, urine analysis, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were done at baseline and at weeks 4, 8, and 12. In this 12-week study, etanercept demonstrated rapid and significant improvement in the ASAS20 response criteria (91.3%), at as early as 2 weeks of therapy (71.3%). Partial remission of AS was achieved in 49.3% of patients after 12 weeks of treatment. Disease activity (BASDAI) and function (BASFI) were also significantly improved after 12 weeks etanercept treatment (p < 0.0001 and p < 0.0001, respectively). In addition, significant increase of chest expansion (2.77 ± 1.69 cm versus 3.56 ± 1.82 cm, p = 0.0004) and lumbar flexion (2.11 ± 2.76 cm versus 2.58 ± 3.42 cm, p = 0.0075) and significant reduction of occiput-to-wall distance (6.59 ± 7.14 cm versus 5.32 ± 6.65 cm, p = 0.0006) were also demonstrated. Both ESR and CRP declined significantly after patients were treated with etanercept. There were no severe adverse effects during the treatment period. Etanercept is generally safe, well tolerated, and effective in Chinese patients with severe AS. Clinical efficacy, including partial remission and BASDAI, is even better in Chinese than in Caucasian patients. Further study is required to assess long-term efficacy and safety in Chinese patients with AS. ? 2010 Japan College of Rheumatology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650514551&doi=10.1007%2fs10165-010-0334-2&partnerID=40&md5=90e86d3052ca3ee950b887ab5f8a8853 https://scholars.lib.ntu.edu.tw/handle/123456789/542194 |
ISSN: | 1439-7595 | DOI: | 10.1007/s10165-010-0334-2 | SDG/關鍵字: | C reactive protein; etanercept; adult; ankylosing spondylitis; article; blood analysis; blood chemistry; Caucasian; Chinese; clinical article; controlled study; drug efficacy; drug response; erythrocyte sedimentation rate; female; human; male; priority journal; questionnaire; race difference; urinalysis; Adult; Antirheumatic Agents; Asian Continental Ancestry Group; European Continental Ancestry Group; Female; Health Status; Humans; Immunoglobulin G; Male; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor; Recovery of Function; Remission Induction; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。